🔗 Share this article

An everyday slimming pill could assist people cut their weight by as much as 20%, as per a study that could pave the way for countless people more people to shed pounds.

How the Drug Functions

This medication, known as the oral treatment, focuses on the same GLP-1 receptors as weight loss injections such as tirzepatide and semaglutide. During research of over 3,000 participants, one in five people who took the daily pill for more than a year shed at least one-fifth of their body weight.

Weight loss injections have been revolutionary, but oral forms are seen as a holy grail since they are easier to keep, share and administer, and are also projected to be cheaper, providing new optimism for millions attempting to reduce weight.

Orforglipron is a GLP-1 agonist, a type of drug that helps reducing glucose levels, delays the breakdown of food and may curb hunger.

Study Findings and Convenience

The weight loss observed in participants using the tablet are less dramatic as that among patients taking injectable alternatives, but specialists believe the tablet will be more accessible and user-friendly compared with injections.

The drug is not yet authorized by the FDA or health authorities in other countries. The manufacturer has said it expects significant interest once the new pill is released.

In the study, the over three thousand participants were divided into cohorts receiving the medication tablets of varying strengths, while some received a dummy pill, for 72 weeks.

All of the volunteers were diagnosed with excess weight, indicating they had a BMI score of 30 or higher, but they were free from high blood sugar. Participants from several nations were involved in the research.

Significant Outcomes

Researchers found that following 72 weeks users on the lowest dose reduced an average of 7.5% of their weight. Participants on the highest dose lost an average of over 11% of their weight.

Among patients taking the highest doses, more than half had a reduction of 10% or more of weight, 36% had a loss of 15% or greater, and almost one-fifth had a reduction of 20% or higher.

Researchers said other health metrics additionally got better among participants using the drug, such as better BP, a smaller waist circumference and a decrease in bad cholesterol.

Frequent side-effects were gastrointestinal, which were described as mild to moderate.

“In adults diagnosed with obesity, 72-week treatment using orforglipron led to significantly greater decreases in weight than inactive treatment,” researchers noted.

Potential Impact

Medical experts have praised slimming treatments as transformative. But shots come with extra logistical efforts for health services, so tablet forms could benefit millions more individuals trying to slim down.

Additional studies indicates slimming jabs could be effective on minors starting from age six who are obese or have diabetes. But, digestive issues were “significantly more common” in young users using the drugs.

They said that extended follow-up durations in future trials and more real-world analysis were crucial to establish the long-term impacts.”